Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The index has shown a price gain of 15.75% this year. Over the last six months, there has been a stronger performance of -32.88%. The price of IKT fallen by 22.50% during the last 30 days period. For the last 5-days stocks have improved 16.67%.
Inhibikase Therapeutics Inc’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $3.82 on 01/25/24 and a low of $0.80 for the same time frame on 11/21/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of IKT Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Inhibikase Therapeutics Inc’s current trading price is -61.52% away from its 52-week high, while its distance from the 52-week low is 84.19%. The stock’s price range during this time has been between $0.80 and $3.82. The trading volume for the Healthcare sector company’s shares reached about 0.68 million for the day, which was higher than the average daily volume of 0.33 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Inhibikase Therapeutics Inc (IKT) has experienced a quarterly decline of -1.34% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 10.97M and boasts a workforce of 8 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.4083, with a change in price of -0.3900. Similarly, Inhibikase Therapeutics Inc recorded 232,114 in trading volume during the last 100 days, posting a change of -20.97%.
IKT’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for IKT stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.01.
IKT Stock Stochastic Average
Today’s raw stochastic average for Inhibikase Therapeutics Inc over the last 50 days is 46.05%.This indicates a increase from the raw stochastic average of the past 20 days, which was 46.05%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 29.39% and 25.29%, respectively.
